Clinicians have tools to identify potentially inappropriate medications (PIMs) in older adults—but what about adults under 65? A new protocol led by our researchers outlines an international modified Delphi study to build expert consensus on PIMs for adults aged 18–65 years. 🔗 tinyurl.com/kpyyverh

Yesterday, the JAMA Network Open Editorial Board met to discuss plans for the journal, which is dedicated to improving health care and advancing health equity worldwide through the open-access dissemination of research across all health disciplines.

Adjusted analysis demonstrates lower controller inhaler use in Asian, Black, and Hispanic adults with #Asthma than in White adults, despite accounting for clinical, socioeconomic, and health care access factors. ja.ma/3PMQfIs

New simultaneous 📝 at #ATS2026 out in @jama.com: Disparities in Inhaler Utilization Among US Adults w. Asthma. The number to remember: 37%. Only 37% used inhaled corticosteroids (ICS), the cornerstone of guideline-based asthma treatment w large racial/ethnic gaps. jamanetwork.com/journals/jam...

This #PharmacoequityFriday I’m sharing new research from our team out this week in @jamanetworkopen.com. In a study of 1.6 million adults, we found that folks w. #AFib had >$11 K ⬆️ in annual medical costs (including nearly $2K ⬆️ for 💊💊) vs. those w/o AFib. 📝: jamanetwork.com/journals/jam...

A success story for a physician with Alzheimer's which, in spite of the obstacles outlined, is a precursor for our enhanced ability to prevent the disease in the future gift link www.wsj.com/opinion/i-ca...

Thrilled to hear @uressien.bsky.social at @dukemedschool.bsky.social speaking on Pharmacoequity

Glad to have contributed to this study examining #Pharmacoequity of newer disease modifying therapies for patients with rheumatoid arthritis. Take a look at our paper below! 📝: www.jrheum.org/content/52/1...

Racial and Ethnic Disparities in Disease-Modifying Antirheumatic Drug Use Among Adults With Rheumatoid Arthritis in the United States

To the Editor: Rheumatoid arthritis (RA) imposes substantial clinical and economic burdens worldwide.1 Disease-modifying antirheumatic drugs (DMARDs) can control RA symptoms and prevent joint degene...

jrheum.org

MedPage Today@medpagetoday.com · 10mo ago

Use of DMARDs for RA was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis of federal survey data indicated, even after adjusting for income, education, & other factors. @uressien.bsky.social www.medpagetoday.com/rheumatology...

Pharmacoequity turned 4 years old last month! Had a wonderful time in Ann Arbor last week as this year’s McKesson Equity Series Speaker @ the University of Michigan College of Pharmacy sharing on the past, present, and future of this growing field. Let’s work together to achieve #Pharmacoequity! 💊

Had a wonderful time at the National Academy of Medicine (@nam.edu) Annual Meeting last week, kicking off Year 2 of the Emerging Leaders in Health and Medicine! ✨ Always great to connect with mentors, role models, and friends at this meeting and to celebrate the new inductees into the Academy.

Every Wednesday evening for years I’ve opened the @nejm.org weekly email to dozens of the latest clinical trials of exciting new therapies. Yet, the future diffusion and equitable dissemination & implementation of these drugs is FAR less studied. So many opportunities to advance #Pharmacoequity. 💊

Love the idea of a series focused on tobacco cessation globally, esp the role of #Pharmacoequity. 💊 But not sure there is evidence to support that it’s “lagging knowledge” driving ⬇️ rates of treatment in low and middle income countries. 🤔 Hoping for more data ahead. www.nejm.org/doi/full/10....

My patient recently lost his Medicaid insurance and couldn’t afford his meds. Just calculated the cost of his 13 💊 which would be $2300/month. That’s around $27,500/year. The FPL for a family of 4 is ~$32,000. This is not sustainable for the health and lives of our patients! #Pharmacoequity

Walked into a #RiteAid in CA yday that was EMPTY. Sad. “The hundreds of stores that are set to close within the year will limit many Americans' access to 💊 resulting in "pharmacy deserts"—less-connected communities being left w/o nearby drugstores. #Pharmacoequity www.newsweek.com/rite-aid-cvs...

Rite Aid closures reach 1,000 as America faces "pharmacy deserts"

The ongoing closure of pharmacies across the country continues to threaten Americans' access to vital medications.

newsweek.com

In this week’s newsletter, we’re celebrating the well-deserved recognition our faculty and trainees have earned for their impact across education, research, clinical care, and community engagement. Read about the latest honors and achievements here: uclahs.fyi/3GZDVQQ

What an outstanding @cudeptofmedicine.bsky.social grand rounds presentation by the inspiring @uressien.bsky.social ! #pharmacoequity "Pursuing Pharmacoequity: The Case of Atrial Fibrillation"

Sharing a short thread here on our recent publication from earlier this month. This project was an incredible team effort, and truly would not have been possible without every co-author on this all-⭐ team! Go give it a read here if interested: jamanetwork.com/journals/jam... A short 🧵: (1/x)

‼️ New Simultaneous 📝 at #SGIM25. In 2023, lecanemab became the 1st disease-modifying 💊 for Alzheimer’s disease. Led by 🌟 Frank Zhou, we found that early uptake of lecanemab still appears to be marked by racial, ethnic & socioeconomic disparities. jamanetwork.com/journals/jam... #Pharmacoequity

Congrats to the amazing, Renu! ✨

Society of General Internal Medicine (SGIM)@societygim.bsky.social · last yr.

🎉 Congratulations to our #SGIM25 Award Winner! 🎉 Please join us in celebrating Renuka Tipirneni, MD, MSc, recipient of the Mid-Career Research Mentorship Award. Their outstanding work exemplifies excellence in general internal medicine. 👏 Help us congratulate Renuka in the comments!

Pharmacoequity matters. Appreciate this work! #AGS25 @uressien.bsky.social

📋‼️Honored to share this newly published article that I helped lead! Cannot thank @uressien.bsky.social enough - he has served as a friend, mentor, and sponsor throughout! And the whole study team who this wouldn’t have happened without!🙏🏽 Will post a longer thread on the findings soon - stay tuned!

‼️ NEW Paper. Led by @sudkrishnamurthy.bsky.social we found wide disparities in receipt of ERBB2-targeted 💊 for Medicare enrollees w. breast cancer, disparities that did narrow by 2019. We need more research to identify strategies to improve cancer #Pharmacoequity. jamanetwork.com/journals/jam...

Our new editorial in JAMA Network Open: Lower rates of high-risk med use in minoritized Medicare beneficiaries may reflect access barriers, not better care. Highlights urgent need for equity in deprescribing practices & alternatives to PIMs. With @uressien.bsky.social jamanetwork.com/journals/jam...

In people with diabetes, GLP-1 and SGLT2i drugs were associated with less Alzheimer's disease and related dementias jamanetwork.com/journals/jam...

NEW Academic Achievement Unlocked: Fellow of the American College of Physicians! ✨😅 Grateful to Dr. Eileen Barrett for the nomination and to my Dad, the first and best internal medicine doctor I know. 🤎👨🏾‍⚕️ #FACP cc @gradydoctor.bsky.social

“…11% of people said they could not afford medication and care within the past 3 months, the highest level in the four years the survey has been conducted. Over 1/3 said if they were to need medical care, they would not be able to pay for it.” #Pharmacoequity www.nytimes.com/2025/04/02/h...

More Americans Cannot Afford Medical Care: Gallup Poll

A new survey found that 11 percent of Americans said they could not pay for medication and medical treatments.

nytimes.com

"In labs around the world, scientists are using A.I. to search among existing medicines for treatments that work for rare diseases." And saving some lives. @davidfajgenbaum.bsky.social gift link www.nytimes.com/2025/03/20/w...

Drugs Have Uses We Can’t Imagine. He’s Using A.I. to Find Them. (Gift Article)

Scientists are using machine learning to find new treatments among thousands of old medicines.

nytimes.com

Sharing my new JAMANetworkOpen study, showing disparities in patient-clinician communication experiences of adults with/without serious illness: jamanetwork.com/journals/jam.... Compared to those without, adults with serious illness were more likely to feel afraid to ask questions, 1/

Patient-Clinician Communication Among Adults With and Without Serious Illness

This cross-sectional study assesses patient-clinician communication experiences for adults with and without serious illness, focusing largely on relational and identity goals.

jamanetwork.com

99% of new medicines developed by the pharmaceutical industry depend on NIH research jamanetwork.com/journals/jam...

Comparison of Research Spending on New Drug Approvals by the NIH vs the Pharmaceutical Industry

This cross-sectional study examines National Institutes of Health and pharmaceutical industry investments in recent drug approvals.

jamanetwork.com

Had the pleasure of being invited (virtually) to both the University of Iowa College of Medicine and College of Dentistry to serve as a Distinguished Lecturer. 🖤💛 We need more than just talk right now to bring us closer to justice in health, but hoping to help inspire the future.